JP6479812B2 - 細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ - Google Patents

細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ Download PDF

Info

Publication number
JP6479812B2
JP6479812B2 JP2016537859A JP2016537859A JP6479812B2 JP 6479812 B2 JP6479812 B2 JP 6479812B2 JP 2016537859 A JP2016537859 A JP 2016537859A JP 2016537859 A JP2016537859 A JP 2016537859A JP 6479812 B2 JP6479812 B2 JP 6479812B2
Authority
JP
Japan
Prior art keywords
combination
compound
alk
inhibitor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016537859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529285A5 (OSRAM
JP2016529285A (ja
Inventor
レスリー ハリス，ジェニファー
レスリー ハリス，ジェニファー
リ，ナンシン
アール． スミス，ティモシー
アール． スミス，ティモシー
モセ，ヤエル
ウッド，アンドリュー
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2016529285A publication Critical patent/JP2016529285A/ja
Publication of JP2016529285A5 publication Critical patent/JP2016529285A5/ja
Application granted granted Critical
Publication of JP6479812B2 publication Critical patent/JP6479812B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016537859A 2013-08-28 2014-08-28 細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ Expired - Fee Related JP6479812B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361871275P 2013-08-28 2013-08-28
US61/871,275 2013-08-28
PCT/US2014/053244 WO2015031666A1 (en) 2013-08-28 2014-08-28 Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases

Publications (3)

Publication Number Publication Date
JP2016529285A JP2016529285A (ja) 2016-09-23
JP2016529285A5 JP2016529285A5 (OSRAM) 2017-11-02
JP6479812B2 true JP6479812B2 (ja) 2019-03-06

Family

ID=51541330

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016537859A Expired - Fee Related JP6479812B2 (ja) 2013-08-28 2014-08-28 細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ

Country Status (12)

Country Link
US (2) US20160361314A1 (OSRAM)
EP (1) EP3038652B1 (OSRAM)
JP (1) JP6479812B2 (OSRAM)
KR (1) KR20160047521A (OSRAM)
CN (1) CN106029099A (OSRAM)
AU (3) AU2014312261A1 (OSRAM)
BR (1) BR112016004358A8 (OSRAM)
CA (1) CA2922684A1 (OSRAM)
ES (1) ES2674361T3 (OSRAM)
MX (1) MX2016002580A (OSRAM)
RU (1) RU2016110874A (OSRAM)
WO (1) WO2015031666A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021100677A1 (ja) 2019-11-18 2021-05-27 中外製薬株式会社 併用医薬

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016167511A2 (ko) * 2015-04-14 2016-10-20 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
KR101772134B1 (ko) 2015-04-14 2017-08-29 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US11208630B2 (en) * 2015-12-24 2021-12-28 University Of Florida Research Foundation, Incorporated AAV production using suspension adapted cells
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
WO2019136451A1 (en) 2018-01-08 2019-07-11 G1 Therapeutics, Inc. G1t38 superior dosage regimes
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CA3130706A1 (en) * 2019-04-04 2020-10-08 Dana-Farber Cancer Institute, Inc. Cdk2/5 degraders and uses thereof
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202146017A (zh) * 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
CN116261455B (zh) * 2020-09-25 2024-11-01 苏州亚盛药业有限公司 一种药物组合物及其在治疗癌症中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53588B1 (sr) * 2006-12-08 2015-02-27 Irm Llc Jedinjenja i kompozicije kao inhibitori protein kinaza
BRPI0720264B1 (pt) * 2006-12-08 2022-03-03 Novartis Ag Compostos e composições como inibidores de proteína cinase
ES2522346T3 (es) * 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
EP3718560A3 (en) * 2009-05-13 2020-12-09 The University of North Carolina at Chapel Hill Cyclin dependent kinase inhibitors and methods of use
US20130035336A1 (en) * 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
ME02200B (me) * 2011-02-02 2016-02-20 Novartis Ag Postupci za korisćenje alk inhibitora

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021100677A1 (ja) 2019-11-18 2021-05-27 中外製薬株式会社 併用医薬
KR20220101656A (ko) 2019-11-18 2022-07-19 추가이 세이야쿠 가부시키가이샤 병용 의약

Also Published As

Publication number Publication date
WO2015031666A1 (en) 2015-03-05
JP2016529285A (ja) 2016-09-23
EP3038652A1 (en) 2016-07-06
EP3038652B1 (en) 2018-03-21
CA2922684A1 (en) 2015-03-05
AU2017219093A1 (en) 2017-09-14
BR112016004358A8 (pt) 2020-02-11
US20160361314A1 (en) 2016-12-15
AU2018236813A1 (en) 2018-10-18
AU2014312261A1 (en) 2016-03-10
ES2674361T3 (es) 2018-06-29
RU2016110874A (ru) 2017-10-04
CN106029099A (zh) 2016-10-12
RU2016110874A3 (OSRAM) 2018-06-27
US20180318305A1 (en) 2018-11-08
MX2016002580A (es) 2016-10-26
KR20160047521A (ko) 2016-05-02

Similar Documents

Publication Publication Date Title
JP6479812B2 (ja) 細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ
JP6532878B2 (ja) 組合せ医薬
JP6855243B2 (ja) 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
JP6644042B2 (ja) ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ
KR20160020502A (ko) 제약 조합물
KR20140072028A (ko) Pi3k- 및 mek-억제제의 상승작용적 조합물
CN107249638A (zh) 阿匹莫德用于治疗肾癌
KR20120097496A (ko) 조합물
CN121059617A (zh) 包含Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂的组合产品及其用途
EP3030237A1 (en) Pim kinase inhibitor combinations
KR20160090814A (ko) Jak, cdk 및 pim의 억제제를 포함하는 조합 요법
KR20140044362A (ko) 피라지노-트리아진 유도체를 포함하는 비소세포성폐암 예방 및 치료용 조성물
KR20120099219A (ko) 조합물
CN112237579B (zh) 药物组合及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190206

R150 Certificate of patent or registration of utility model

Ref document number: 6479812

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees